D&D Pharmatech (A347850) Stock Overview
A clinical-stage biotech company, develops medicines in South Korea and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A347850 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
D&D Pharmatech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩200,500.00 |
| 52 Week High | ₩239,500.00 |
| 52 Week Low | ₩32,350.00 |
| Beta | 0 |
| 1 Month Change | 28.77% |
| 3 Month Change | 75.26% |
| 1 Year Change | 383.72% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 449.32% |
Recent News & Updates
Shareholder Returns
| A347850 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.5% | 1.6% | 4.5% |
| 1Y | 383.7% | 21.7% | 34.3% |
Return vs Industry: A347850 exceeded the KR Biotechs industry which returned 21.7% over the past year.
Return vs Market: A347850 exceeded the KR Market which returned 34.3% over the past year.
Price Volatility
| A347850 volatility | |
|---|---|
| A347850 Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 10.4% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A347850's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A347850's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 21 | Seul-ki Lee | www.ddpharmatech.com |
D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical trials to treat NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03 that is in Phase I clinical trials for the treatment of PD, AD, and neuroinflammation; PMI04, which is in Phase I clinical trials to treat PD, AD, ALS, and depression; and PMI05 and PMI06 that are in Phase I clinical trials for the treatment of oncology and immuno-oncology.
D&D Pharmatech Inc. Fundamentals Summary
| A347850 fundamental statistics | |
|---|---|
| Market cap | ₩2.18t |
| Earnings (TTM) | -₩37.11b |
| Revenue (TTM) | ₩9.33b |
Is A347850 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A347850 income statement (TTM) | |
|---|---|
| Revenue | ₩9.33b |
| Cost of Revenue | ₩26.43m |
| Gross Profit | ₩9.31b |
| Other Expenses | ₩46.41b |
| Earnings | -₩37.11b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.42k |
| Gross Margin | 99.72% |
| Net Profit Margin | -397.57% |
| Debt/Equity Ratio | 0% |
How did A347850 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 11:33 |
| End of Day Share Price | 2025/10/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
D&D Pharmatech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.